AEHR TEST SYSTEMS
No SEC Form 4 filings for $AEHR in the last 30 days.
See all $AEHR insider activity →Aehr Test Systems (AEHR) stock rose 7.06% on strong semiconductor test demand and AI-driven growth prospects. Oppenheimer initiated an Outperform rating with a $120 target, citing a $41M hyperscaler order. AEHR reported $18.8M revenue, $1.39M net income, and a strong balance sheet. The stock has gained 32% in a month, driven by AI and EV themes.
Wall Street analysts expect three chip companies to triple revenue. Lumentum (LITE) forecasts $13.7B by 2029, driven by AI data center demand. Aehr Test Systems (AEHR) projects $271M by 2029, fueled by AI chip testing. Navitas Semiconductor (NVTS) anticipates $200M by 2029, pivoting to AI infrastructure. Growth depends on customer orders, product launches, and market demand.
Aehr Test Systems (AEHR) stock falls 7.5% in morning trading, extending a decline from September 22. The drop follows a Zacks Research downgrade to 'hold' and recent insider selling. Analysts have mixed views, with Oppenheimer and Jefferies issuing positive ratings. The stock trades near $93.05, well below its 52-week high of $147.40, amid a broader market decline.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning AEHR (AEHR TEST SYSTEMS). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent AEHR coverage spans market movers, earnings and financial news.
The new contract and analyst upgrade provide a fresh catalyst that could sustain momentum and justify short‑term buying.
Guidance indicates rapid growth for Aehr, driven by AI chip burn‑in demand.
The stock is under pressure from a recent downgrade and insider sales, likely leading to further downside.
Outperform rating signals above‑average expectations.
Buy rating may lift the semiconductor test equipment maker.
AlphAI scores every news story that mentions AEHR with an AI model for sentiment and relevance, and aggregates insider trades from AEHR TEST SYSTEMS's SEC EDGAR Form 4 filings. Figures refresh continuously.
Aehr Test Systems (AEHR) stock rose 7.06% on strong semiconductor test demand and AI-driven growth prospects. Oppenheimer initiated an Outperform rating with a $120 target, citing a $41M hyperscaler order. AEHR reported $18.8M revenue, $1.39M net income, and a strong balance sheet. The stock has gained 32% in a month, driven by AI and EV themes.
2 min readWall Street analysts expect three chip companies to triple revenue. Lumentum (LITE) forecasts $13.7B by 2029, driven by AI data center demand. Aehr Test Systems (AEHR) projects $271M by 2029, fueled by AI chip testing. Navitas Semiconductor (NVTS) anticipates $200M by 2029, pivoting to AI infrastructure. Growth depends on customer orders, product launches, and market demand.
3 min readAehr Test Systems (AEHR) stock falls 7.5% in morning trading, extending a decline from September 22. The drop follows a Zacks Research downgrade to 'hold' and recent insider selling. Analysts have mixed views, with Oppenheimer and Jefferies issuing positive ratings. The stock trades near $93.05, well below its 52-week high of $147.40, amid a broader market decline.
2 min readAnalysts initiated coverage on five companies: Goldman Sachs rated Abivax Buy with $155 PT, BTIG rated Amer Sports Buy with $42 PT, Morgan Stanley rated Coinbase Equal-Weight with $250 PT, Oppenheimer rated Aehr Test Outperform with $120 PT, and Piper Sandler rated Intel Neutral with $110 PT. All companies closed below their respective targets on Wednesday.
1 min readAnalysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.
3 min readCaleres Inc (CAL) reported Q2 earnings of $0.47 per share, beating estimates of $0.37, and raised FY26 EPS guidance. Shares rose 14.4% to $13.76. Other companies like Opus Genetics (IRD), Signet Jewelers (SIG), and Flotek Industries (FTK) also saw significant gains due to positive updates.
2 min readAehr Test Systems (AEHR) is gaining momentum in AI semiconductor testing, securing orders from major customers. It expects $130M-$150M in fiscal 2027 revenue, up 2.6-3x from 2026. The company faces competition from Teradyne (TER) and FormFactor (FORM).
2 min readUS equities show divergence with semiconductor and biotech stocks rising, while software stocks fall. Belite Bio (BLTE) and Aehr Test Systems (AEHR) lead gains, while Guidewire Software (GWRE) and lululemon (LULU) lead declines. SanDisk (SNDK), Cohu (COHU), and Cerebras Systems (CBRS) also see notable gains. Fair Isaac (FICO), UiPath (PATH), and Asana (ASAN) experience significant drops.
2 min readAehr Test Systems (AEHR) stock rose 40% after reporting Q4 earnings beat with $18.84M revenue, $3.6M net income, and record bookings. FY27 revenue guidance raised to $130M-$150M, above consensus. Backlog at $80.6M, cash at $116.5M. Retail sentiment turned bullish.
2 min readAehr Test Systems (AEHR) shares rose 13.1% on Friday ahead of investor meetings next week. CEO Gayn Erickson highlighted the company's role in semiconductor testing for AI and EV markets. Hedge fund holdings surged 678% QoQ to $473.97M, driven by AI infrastructure demand. The stock also benefited from a broader semiconductor sector rally.
2 min read
